Referral Resource
For Doctors
Clinical reference guide for haematologists, oncologists, and general physicians considering BMT referral.
Clinical Reference
When to Refer for BMT
A consolidated reference of BMT indications organised by condition, extracted from Dr. Suparno Chakrabarti's clinical guidelines.
| Condition | BMT Indication | Type of BMT | Timing |
|---|---|---|---|
| Thalassemia Major | Only curative treatment | Allogeneic (incl. Haploidentical) | Best age 2–5 years; earlier is better |
| Sickle Cell Disease | Severe disease; 90% cure with matched donor | Allogeneic (incl. Haploidentical) | Before end-organ damage |
| Aplastic Anemia (Severe/Very Severe) | Treatment of choice for young patients with matched sibling donor | Allogeneic (incl. Haploidentical) | Early; avoid multiple transfusions |
| ALL — High Risk / MRD+ | High Risk ALL; positive MRD after chemotherapy; relapsed ALL/ post CAR-T induced remission | Allogeneic (incl. Haploidentical) | First complete remission |
| AML (non-APML) | All AML except good risk or APML; relapsed AML | Allogeneic (incl. Haploidentical) | First complete remission |
| CML — TKI-resistant / Accelerated / Blast Crisis | Failed TKI therapy; accelerated phase; blast crisis | Allogeneic (incl. Haploidentical) | As soon as failure of two lines of TKI confirmed/ Immediately at transformation |
| Hodgkin's Lymphoma (Relapsed) | Relapsed/refractory HL; after autologous BMT failure | Autologous → Allogeneic (incl. Haploidentical) (if relapsed after auto) | After salvage chemotherapy |
| NHL (Relapsed/High Risk) | Relapsed NHL; T cell NHL; Mantle Cell; relapsed low grade | Autologous/ CAR-T cell therapy → Allogeneic (incl. Haploidentical) | PET-negative before BMT = 80% cure |
| MDS | Only curative treatment; early- before infections/iron overload | Allogeneic (incl. Haploidentical) | Before progression to high IPSS-M/ AML/ life-threatening complications |
| Primary Immunodeficiency (SCID etc.) | Definitive cure; urgently at diagnosis for SCID | Allogeneic (incl. Haploidentical) | Ideally <3.5 months for SCID |
| Inherited Bone Marrow Failure | Before onset of leukemia/MDS or excessive transfusions | Allogeneic (incl. Haploidentical) | Early, as an elective procedure |
| Inherited Metabolic Disorders | Before significant neurological damage | Allogeneic (incl. Haploidentical) | Early childhood |
| Autoimmune Disease (Severe) | Scleroderma, MS — when conventional treatments fail | Autologous or Allogeneic (incl. Haploidentical) | Before permanent organ damage |
Our Expertise
Research & Credentials
Led by internationally trained specialists. Meet our full team →
125+ Peer-Reviewed Publications · 4,700+ Citations
Our team has published extensively on Haploidentical BMT, post-transplant viral infections, and immune reconstitution. We were the first in the world to identify novel GvHD prophylaxis protocol (Abatacept + PTCy), which is now globally acknowledged and standard of care. Every treatment protocol is backed by rigorous research.
The only Indian centre with indigenous novel cellular therapies for refractory blood cancers.
Selected Key Papers
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery
Blood · 2002 · Chakrabarti S, Mautner V, Osman H, et al.
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Blood · 2002 · Chakrabarti S, Mackinnon S, Chopra R, et al.
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality
British Journal of Haematology · 2002 · Chakrabarti S, Avivi I, Mackinnon S, et al.
Haploidentical Family Donor Transplantation: At the Crossroads of a Changing Paradigm
Advances in Hematology · 2016 · Chakrabarti S
Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study
Bone Marrow Transplantation · 2001 · Chakrabarti S, Collingham K, Holder K, et al.
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections
Bone Marrow Transplantation · 2001 · Chakrabarti S, Collingham K, Osman H, et al.
Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy
Bone Marrow Transplantation · 1999 · Chakrabarti S, Collingham KE, Fegan C, Milligan DW
Post-transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion
Bone Marrow Transplantation · 2003 · Chakrabarti S, et al.
EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning
Leukemia & Lymphoma · 2007 · Cohen JM, Cooper N, Chakrabarti S, et al.
Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome
Bone Marrow Transplantation · 2003 · Chakrabarti S, Osman H, Collingham K, et al.
View the full publication list
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
2012
2009
2008
2007
2004
2003
2002
2001
2000
1998
Showing 10 landmark papers above; the full list contains 131 publications. View the complete list on ResearchGate or search PubMed.
Get Started
Refer a Patient
Send a Referral
Teleconsultation Available
We offer teleconsultation for remote physician-to-physician consultation on complex cases and BMT suitability assessment.
Modes: Phone call · Text/WhatsApp · Video call
Contact for Referral